Apollomics (APLM) Retained Earnings (2021 - 2025)
Apollomics' (APLM) quarterly Retained Earnings came in at -$711.8 million in Q4 2025, down 1.56% year-over-year from -$723.0 million in Q4 2024, and little changed quarter-over-quarter from -$713.4 million in Q2 2025.
Analysis
Apollomics (APLM) Retained Earnings (2021 - 2025) Analysis & Trends
Apollomics (APLM) has reported Retained Earnings for 5 consecutive years, with -$711.8 million the latest figure, recorded in Q4 2025.
- On a quarterly basis, Retained Earnings fell 1.56% year-over-year to -$711.8 million in Q4 2025; TTM through Dec 2025 was -$711.8 million, a 1.56% decrease from a year earlier, with the FY2025 full-year figure at -$711.8 million, down 1.56% from the prior year.
- Retained Earnings was -$711.8 million for Q4 2025 at Apollomics, roughly flat from -$713.4 million in the prior quarter.
- Over five years, Retained Earnings peaked at -$281672.0 in Q2 2022 and troughed at -$713.4 million in Q2 2025.
- A 5-year average of -$532.3 million and a median of -$647.0 million in 2023 frame the typical range for Retained Earnings.
- Across the five-year window, Retained Earnings tumbled 221823.37% in 2023 and retreated 1.56% in 2025, its largest moves.
- Over 5 years, Retained Earnings stood at -$235.4 million in 2021, then plunged by 101.58% to -$474.6 million in 2022, then slumped by 36.32% to -$647.0 million in 2023, then fell by 8.32% to -$700.8 million in 2024, then slipped by 1.56% to -$711.8 million in 2025.
- The last three Retained Earnings figures came in at -$711.8 million (Q4 2025), -$713.4 million (Q2 2025), and -$700.8 million (Q4 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | -22.28 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 9.53 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 15.69 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 37.62 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 558.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 20.97 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 5.13 Bn |
| 10 | Apollomics | 34.50 Mn | 31.23 Mn | - | -711.76 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -711.76 Mn |
| Jun 30, 2025 | -713.36 Mn |
| Dec 31, 2024 | -700.82 Mn |
| Jun 30, 2024 | -682.17 Mn |
| Dec 31, 2023 | -646.97 Mn |
| Jun 30, 2023 | -625.10 Mn |
| Dec 31, 2022 | -474.60 Mn |
| Jun 30, 2022 | -281,672.00 |
| Dec 31, 2021 | -235.44 Mn |